Trial · NCT05675449
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449, Phase 1, Active not recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma. Trials, record NCT05675449. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05675449
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- NCT number
- NCT05675449
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 59 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Carfilzomib, Maplirpacept
- First posted
- 2023-01-09
- Last updated
- 2026-08-13
Source ClinicalTrials.gov
Registered outcomes50
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1 Number of participants with dose limiting toxicity (DLT) | From first dose of elranatamab through the end of the first cycle of combination treatment, about 42 days. | Dose limiting toxicity rate based on dose limiting toxicity evaluable participants. |
| Primary | Part 2A Number of participants with dose limiting toxicity | From the first dose of maplirpacept through the first cycle of combination treatment, about 64 days. | Dose limiting toxicity based on dose limiting toxicity evaluable participants. |
| Primary | Part 2B Number of participants with dose limiting Toxicity | From first dose of elranatamab through the first cycle of combination treatment, about 42 days. | Dose limiting toxicity rate based on dose limiting toxicity evaluable participants. |
| Secondary | Part 1: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment | Assessed from baseline up to 90 days after last dose of study treatment. | Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category. |
| Secondary | Part 1: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity. | Assessed from baseline up to 90 days after last dose of study treatment. | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. |
| Secondary | Part 1: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities | Accessed from baseline up to 90 days after the last dose of study treatment. | Laboratory abnormalities as characterized by type, frequency, severity. |
| Secondary | Part 1: Percent of participants with Best Overall Response (BOR) | Assessed for approximately 2 years | BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria. |
| Secondary | Part 1: Percentage of Participants with an Objective Response Rate (ORR) | Assessed from enrollment for approximately 2 years. | ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG. |
| Secondary | Part 1: Percentage of participants with a complete response rate (CRR) | Assessed for approximately 2 years | Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator. |
| Secondary | Part 1: Time to Response (TTR) | Assessed for approximately 2 years. | TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed. |
1 to 10 of 50Source ClinicalTrials.gov
See all 50 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05675449
GET https://conductscience.org/api/trials/v1/NCT05675449/registered?page=2